人促红细胞生成素治疗乳腺癌化疗相关性贫血

Clinical Observations on RHuEPO in the Treatment of Breast Cancer Chemotherapy Realated Anemia

目的 :探讨重组人促红细胞生成素 (rHuEPO)治疗乳腺癌化疗相关性贫血的疗效评价。方法 :将 6 7例乳腺癌术后患者随机分为rHuEPO治疗组和对照组。全部病例化疗前血红蛋白≥ 110g L。治疗组 34例 ,化疗联合rHuEPO ;对照组 33例 ,单纯化疗 :化疗方案均为CAF ,均完成 6个周期。结果 :在全部 6个周期的化疗过程中 ,rHuEPO治疗组始终维持稳定的Hb水平 ,而对照组却出现了进行性贫血。化疗结束时 ,对照组Hb下降 (32 1± 11)g L ,而rHuEPO治疗组仅下降 (8 2± 1 2 )g L ,且无 1例出现明显贫血 ,而对照组有 15例出现明显贫血。结论 :在化疗的同时使用rHuEPO可以预防贫血的发生 ,保证化疗顺利进行 。

Objective To evaluate the effect of recombinant human erythropietin (rHuEPO) in the treatment of breast cancer chemotherapy-related anemia.Methods Sixty-seven patients of postoperative breast cancer were randomised into a treatment group,receiving chemotherapy concurrent with rHuEPO,and a control group,receiving chemotherapy only.All patients had hemogloblin level(Hb)≥110 g/L.Results During the treatment,patients received rHuEPO had relatively stable hemogloblin level while the control group developed progressive anemia.After treatment,patients received rHuEPO had a decline of Hb level(8.2±1.2)g/L,while the control group had a significant decline of Hb level (32.1±11)g/L,P<0.01.Conclusion Chemothrapy concurrent with the use of rHuEPO can prevent from developing the treatment-related anemia,guarantee the success of chemotherapy and improve the quality of life.